NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
NCT02343120 2022-04-28
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
BeiGene
Phase 1/2 Completed